Charles River Laboratories (CRL) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.50 per share. This compares to earnings of $2.46 per share a year ago.
Lab services company Charles River Laboratories (NYSE:CRL) reported Q4 CY2024 results exceeding the market’s revenue ...
The Wilmington, Massachusetts-based company said it had a loss of $4.22 per share. Earnings, adjusted for non-recurring costs, were $2.66 per share. The results topped Wall Street expectations.
Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients.
The company said, “The Company is providing financial guidance for 2025. The 2025 revenue outlook assumes relatively stable biopharmaceutical demand trends compared to those experienced during the ...
Reports Q4 revenue $1B, consensus $983.63M. James Foster, chair, president and CEO, said, “Throughout 2024, we have launched initiatives to ...
New York State Teachers Retirement System decreased its holdings in shares of Charles River Laboratories International, Inc. ...
The U.S. president said on Tuesday that he intends to impose auto tariffs "in the neighborhood of 25%" and similar duties on ...
Louisiana State Employees Retirement System cut its position in shares of Charles River Laboratories International, Inc.
Shares of Charles River Laboratories International Inc. CRL advanced 1.58% to $154.39 Tuesday, on what proved to be an ...
Thanks to its capacity to detect patterns and stay consistent, machine learning is a great tool for CNS behaviour studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results